Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus

Heart. 2006 Sep;92(9):1335-7. doi: 10.1136/hrt.2005.083006.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemokine CCL5 / metabolism*
  • Clopidogrel
  • Diabetes Mellitus, Type 2 / blood*
  • Humans
  • Leukocytes, Mononuclear / drug effects*
  • Lymphocyte Activation / drug effects
  • Middle Aged
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacology

Substances

  • Chemokine CCL5
  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine